Alteogen Inc. (196170.KQ), a South Korea-based biopharmaceutical company, announced Wednesday that the European Commission has granted marketing authorization for EYLUXVI, a biosimilar to Eylea, co-developed by its subsidiary, Alteogen Biologics.
Regeneron and Bayer's blockbuster drug Eylea is used to treat ophthalmic conditions, including wet age-related macular degeneration (wAMD) and diabetic macular edema (DME).
EYLUXVI is now approved for use across Europe for wAMD, macular edema secondary to retinal vein occlusion, DME, and myopic choroidal neovascularization.
EYLUXVI is Alteogen's second approved biosimilar, following the launch of its Herceptin biosimilar in China through partner Qilu Pharmaceutical.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.